Complement the hemostatic system: an intimate relationship (Q33415519)

26 July 2017

Complement the hemostatic system: an intimate relationship (English)

1 reference

26 July 2017

Ilene Ceil Weitz

1

1 reference

26 July 2017

1 May 2014

1 reference

26 July 2017

1 reference

26 July 2017

133 Suppl 2

1 reference

26 July 2017

S117-21

1 reference

Thrombosis in patients with paroxysmal nocturnal hemoglobinuria

26 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Human complement control and complement evasion by pathogenic microbes--tipping the balance

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

C1-inhibitor efficiently inhibits Escherichia coli-induced tissue factor mRNA up-regulation, monocyte tissue factor expression and coagulation activation in human whole blood

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Effects of race and ethnicity on the incidence of venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Natural history of paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Targeted therapy for inherited GPI deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Thrombosis in patients with paroxysmal noctural hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Microvesicle-associated tissue factor and Trousseau's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Abnormal platelet adhesion on abdominal vessels in asymptomatic patients with paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Expression of tissue factor pathway inhibitor by endothelial cells and platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Plasmatic coagulation and fibrinolytic system alterations in PNH: relation to clone size

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Cyclosporine induces endothelial cell release of complement-activating microparticles

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Thrombotic microangiopathy with targeted cancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Atypical hemolytic-uremic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Clusters of disease manifestations in patients with antiphospholipid syndrome demonstrated by factor analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

High prevalence of antiphospholipid antibodies in Asian cancer patients with thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Antiphospholipid antibodies in lymphoma: prevalence and clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Management of thrombosis in women with antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Beta2-glycoprotein I as a 'cofactor' for anti-phospholipid reactivity with endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

β₂-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

The pathogenesis of the antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Synthetically modified cellulose (SMC): a cellulosic hemodialysis membrane with minimized complement activation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Antiphospholipid antibodies and malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Activation of complement system in adult T-cell leukemia (ATL) occurs mainly through lectin pathway: a serum proteomic approach using mass spectrometry.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Ascitic complement system in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2814%2950020-5

7 January 2021

10.1016/S0049-3848(14)50020-5

Identifiers

DOI

1 reference

26 July 2017

1 reference

PubMed ID

24862131